$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 69 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEN | Exit | COMPUGEN LTDcall | $0 | – | -57,000 | -100.0% | -0.10% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -424,181 | -100.0% | -0.34% | – |
| IPHA | Exit | INNATE PHARMA S Asponsored ads | $0 | – | -184,046 | -100.0% | -0.34% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -66,812 | -100.0% | -0.38% | – |
| CRIS | Exit | CURIS INCcall | $0 | – | -200,000 | -100.0% | -0.39% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -24,666 | -100.0% | -0.44% | – |
| DNAD | Exit | SOCIAL CAP SUVRETTA HLDS CP | $0 | – | -123,862 | -100.0% | -0.49% | – |
| DNAB | Exit | SOCIAL CAP SUVRETTA HLDS CRP | $0 | – | -123,862 | -100.0% | -0.50% | – |
| DNAC | Exit | SOCIAL CAP SUVRETTA HLD CRPI | $0 | – | -123,862 | -100.0% | -0.50% | – |
| DNAA | Exit | SOCIAL CAP SUVRETTA HLDS CRP | $0 | – | -123,862 | -100.0% | -0.50% | – |
| HLXA | Exit | HELIX ACQUISITION CORP | $0 | – | -131,823 | -100.0% | -0.53% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -160,526 | -100.0% | -0.64% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -100,000 | -100.0% | -0.68% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.93% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -58,190 | -100.0% | -1.08% | – |
| HALO | Exit | HALOZYME THERAPEUTICS INC | $0 | – | -71,009 | -100.0% | -1.16% | – |
| RACB | Exit | RESEARCH ALLIANCE CORP II | $0 | – | -556,890 | -100.0% | -2.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.